Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany.
OBJECTIVE
To evaluate treatment outcomes and resource consumption of patients with neurogenic detrusor overactivity (NDO) before and after botulinum toxin A (Botox) therapy in Germany.


METHODS
In a multi-center, cross-sectional, retrospective cohort study, data of patients with NDO 12 months before and after the first Botox therapy were analyzed.


RESULTS
214 patients (mean age 38 +/- 14.8 years, 145 male, 69 female) with NDO due to spinal cord injury (81%); myelomeningocele (14%), or Multiple Sclerosis (5%) from seven hospitals were included. Mean interval between treatments was 8 months. Following treatment, mean maximum detrusor pressure, maximum cystometric capacity and detrusor compliance improved significantly. Prior to Botox therapy, 68% reported urinary tract infections (UTI), 63% had incontinence episodes, and 58% used incontinence aids. These numbers decreased significantly (p < 0.05) after treatment to 28, 33, and 28%, respectively. In patients using incontinence aids, mean costs per patient decreased from 2euro to 1euro per day, whereas the mean cost of drugs to treat UTIs per patient decreased from 163euro to 80euro per year, respectively.


CONCLUSIONS
This is the first study demonstrating the clinical usefulness of Botox therapy in clinical practice. Successful treatment resulted in lower costs for NDO associated morbidity due to less need for incontinence aids and UTI medication.
Wefer
Björn
B
Klinik für Urologie und Kinderurologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
Ehlken
Birgit
B
Bremer
Jörn
J
Burgdörfer
Harald
H
Domurath
Burkhard
B
Hampel
Christian
C
Kutzenberger
Johannes
J
Seif
Christoph
C
Sievert
Karl D
KD
Berger
Karin
K
Pannek
Jürgen
J
D000328:Adult; D019274:Botulinum Toxins, Type A / Q000191:economics / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D015331:Cohort Studies; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005858:Germany; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008591:Meningomyelocele / Q000150:complications; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications; D011336:Probability; D011788:Quality of Life; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013119:Spinal Cord Injuries / Q000150:complications; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics* / Q000209:etiology; D014563:Urodynamics; D055815:Young Adult
D019274:Botulinum Toxins, Type A
Drugs. 2003;63(2):153-66
12515563
J Urol. 2005 Sep;174(3):984-9
16094019
J Urol. 1992 Feb;147(2):416-8
1732606
Br J Urol. 1984 Dec;56(6):614-7
6534476
Eur Urol. 2004 Apr;45(4):510-5
15041117
Eur Urol. 2006 Mar;49(3):519-27
16413656
World J Urol. 2006 Jun;24(2):224-8
16758253
Eur Urol. 2005 Dec;48(6):984-90; discussion 990
16126328
J Urol. 2009 May;181(5):2181-6
19296983
Neurourol Urodyn. 2006;25(5):441-5
16847942
Eur Urol. 2009 Jan;55(1):100-19
18823697
Arch Phys Med Rehabil. 2002 Mar;83(3):346-51
11887115
J Urol. 2000 Sep;164(3 Pt 1):692-7
10953127
Urologe A. 2007 Mar;46(3):293-6
17295036
J Urol. 2005 Jul;174(1):196-200
15947626
Eur Urol. 2009 Jul;56(1):81-8
19403235
Urology. 2006 Feb;67(2):232-6
16442605
Eur Urol. 2008 Mar;53(3):613-8
17804150
J Urol. 2004 Jul;172(1):240-3
15201783
Urol Int. 2004;73(2):143-8
15331899